SenTiva is the smallest and lightest responsive therapy for drug-resistant epilepsy. Photo: courtesy of Business Wire.

UK-based firm LivaNova has obtained approval from the US Food and Drug Administration (FDA) for its new Vagus Nerve Stimulation (VNS) Therapy System designed to treat drug-resistant epilepsy.

The new system features the SenTiva implantable generator and next-generation VNS Therapy Programming System, which comprises a wireless wand and new user interface on a small tablet.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Intended to deliver physician-directed customisable therapy, the smart technology device is said to have demonstrated the ability to minimise the number and duration of seizures.

LivaNova North America president and Neuromodulation business franchise general manager Jason Richey said: “We created SenTiva and the accompanying VNS Therapy Programming System based on feedback received from patients and physicians to ensure ease of use, better patient care, and cost-effectiveness.

“In addition, SenTiva’s compact size allows for a more comfortable experience for paediatric patients, which is beneficial now that VNS Therapy is the first and only system that is FDA-approved for drug-resistant epilepsy in children as young as four years of age.”

SenTiva comes with a detect-and-respond mode to prevent seizures and for automatic delivery of extra therapy to stop them if they start.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“SenTiva comes with a detect-and-respond mode to prevent seizures and for automatic delivery of extra therapy to stop them if they start.”

The device is designed to collect and log seizure-associated events such as the patient’s body position and heart rate variations.

Compatible with SenTiva and other LivaNova VNS Therapy generators, the VNS Therapy Programming System provides advanced guided programming to allow quick treatment with a single touch.

The system also offers scheduled programming, which enables safe prearrangement of different steps during one visit to a physician’s office, resulting in a gradual and automatic increase of therapy without the need for repeated visits.

Day and night programming of the system is intended to facilitate customisation of the therapy based on the patient’s needs.